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Abstract
Pre-B cells represent the immature stage of the B cell lineage and express genes for the pre-
B cell receptor (preBCR). PreBCR consists of lambda 5 and VpreB and its expression elicits
a rearrangement of the immunoglobulin heavy chain prior to rearrangement of the immu-
noglobulin light chain. The lambda 5 and VpreB form a surrogate light chain, which is a
premature type of light chain immunoglobulin. PreBCR may cooperate or interact with
the IL-7 receptor, which contributes to pre-B cell development. The preBCR distal signal-
ing pathway recruits several adaptor proteins and protein kinases. This review aims to
illustrate the framework of the signaling pathway that contributes to B cell lineage devel-
opment and reconsiders the relationship between the preBCR and IL-7 receptors.
Keywords: pre-B cell receptor, IL-7 receptor, ZFP521, adaptor protein, rearrangement of
immunoglobulin
1. Introduction
B cell lymphocytes develop from common lymphocyte progenitors (CLPs) to form mature B
cells, plasma cells, or memory B cells in close association with immunoglobulin genes (Ig)
rearrangement. Ig rearrangement (IgR) status is a phenotypic marker of immature B cell lineage.
IgR occurs with the stepwise rearrangement of the V, D, and J segments of the immunoglobulin
heavy chain (IgH) and immunoglobulin light chain (IgL) gene chain in the bone marrow.
PreBCR is transiently expressed by developing precursor B cells.
The surrogate light chain is tentatively expressed on the membrane surface, followed by expres-
sion of mature IgL. Surrogate light and heavy chains form preBCR, involving the adaptor pro-
teins CD79a and CD79b (alternatively termed as Igα and Igβ). It is not clear how preBCR reacts
with external derived antigens and contributes to the formation of mature B cell receptors (BCR).
To understand the role of preBCR, it is necessary to elucidate the preBCR distal signaling
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pathway. It is well known that many key kinases participate in the BCR signaling pathway, such
as spleen tyrosine kinase (Syk), bruton’s tyrosine kinase (Btk), B lymphocyte kinase (Blk), and a
transcriptional repressor Blimp (B lymphocyte-induced maturation protein). BP-1 (CD249) is
another key player in the immature B cell lineage. In this article, the preBCR signaling pathway
will be reviewed in reference to the BCR pathway in mice.
The B cell developmental stage has been extensively investigated using surface markers for
the appropriate preBCR antibodies. The best known classification for immature phenotype
markers is the Hardy’s classification fraction (Fr) [1]. These markers range from Fr. A–D (Fr. A:
B220+, IgM-, BP-1-, CD43+, and CD24-; Fr. B: B220+, IgM-, BP-1-, CD43+, and CD24+; Fr. C:
B220+, IgM-, BP-1+, CD43+, and CD24+; Fr. C0: B220+, IgM-, BP-1+, CD43+, and CD24high; and
Fr. D: B220+, IgM-, BP-1-, CD43-, and CD24+) with ongoing IgH recombination [2–4].
2. Signal cascade in pre-B cells
2.1. IL-7 and IL-7R signaling cascade
IL-7 and IL-7R play crucial roles in B cell development that function in parallel with Ig recombi-
nation. IL-7R is a heterodimer of the α chain (CD 127) and the common γ chain (γc chain). IL-7Rα
chains are primarily expressed in thymocytes, dendritic cells, mature T cells, and monocytes.
This molecule is also expressed on the surface of pre-B cell lineages, but not on mature B cell
lineages. In T cells and pre-B cells, the signal cascade via IL-7R recruits Janus kinases (JAKs),
activates the signal transducer and activator of transcription (Stat) by phosphorylation. Among
JAKs, Jak2 lacks Src homology binding domains (SH2/SH3) and JAK homology domains (JH1-
JH7). The carboxy-terminal JH domain contains full kinase function (JH1), while the JH2 domain
has significantly lower kinase activity than the JH1 domain. JAKs are recruited when IL-7 binds
to IL-7R, leading to IL-7R auto-phosphorylation. Phosphorylated tyrosine residues of JAKs bind
Stats with an SH2 domain [5] and Stat is phosphorylated by JAK. Phosphorylated STAT forms a
dimer and translocate to the nucleus. Thereafter, the dimeric STAT binds to the promoter region
containing palindromic gamma interferon activation site (GAS) elements that are positioned
upstream of Bcl-xL, Cyclin D1, pim1, c-myc, and other genes inducing proliferation [6]. Suppres-
sor of cytokine signaling (SOCS) controls this cascade in a feedback manner, because the Socs
gene promoter has the GAS element. The SOCS family negatively controls by binding to JAKs.
For example, the SOCS3 protein can bind to JAK2 kinase and inhibit its activity [7].
JAK2mutations have been implicated in myeloid proliferative disorders such as chronic myeloid
leukemia [8] polycythemia vera [9], primarymyelofibrosis, essential thrombocythemia, and pre-B
or lymphoblasticmature BALL [10]. In these disorders, a change of valine to phenylalanine at the
617 position (V617F) in JAK2 induces higher sensitivity to cytokines such as erythropoietin,
thrombopoietin, and IL-7. In therapies targeting JAK2-STAT5 inhibition, JAK2 mutations are
observed in the poor prognostic BCR-ABL1-like subtypes of pediatric B-cell precursor acute
lymphoblastic leukemia (BCP-ALL). Momelotinib and ruxolitinib were therapeutically effective
for ALL. In the development of the lymphoblastic cells, the JAK-STAT pathway plays an impor-
tant role [10].
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IL-7R expression is also controlled in a developmental stage dependent manner. In parallel
with Ig heavy chain rearrangement in pre-B cells (termed large pre-B or pre-B I), IL-7R
expression augments and gradually decreases with expression of the surrogate light chain,
consisting of VpreB and lambda5. Accordingly, the enhanced effect of the IL-7R signaling
cascade is limited to the large pre-B or pre-B I stage. Accordingly, the pre-B ALL phenotype
may depend on the IL-7R pathway. Thus, the activated pathway may determine the tumor
phenotype. In the bone marrow, stromal cells actively produce IL-7 and promote the
proliferation of bone marrow pre-B cells. Cytokine dependency is also observed in T cell
leukemia/lymphoma and Human T-cell Leukemia/lymphoma Type 1 (HTLV-I)-induced
adult T cell leukemia/lymphoma. When the pre-B cells develop immature-B cells, such
dependency on the IL-7 and IL-7R pathway is lost and immature-B cells are recruited to
extra-bone marrow area. In contrast, the excess IL-7R expression on the tumor progenitor
cells may be activated by lower IL-7 in the peripheral environment, which may result in
tumor development. However, the effect of IL-7 on human and mouse pre-B cells are diff-
erent for proliferation and there have been reports that IL-7 may not be an essential factor
in human cells.
Further, the relationship between IL-7R and Jak-STAT during Ig rearrangement remains con-
troversial. In a previous study, MLV-integration based Stat5 activation was observed in pre-B
cell lymphomas in an inbred strain of SL/Kh mice [9]. However, the dependency of prolifera-
tion on IL-7R is a part of lymphomagenesis, because the genetic background or microsatellite
instability unique to this strain is also required [18]. For this reason, Stat5 activation is not
sufficient for pre-B cell lymphoma or ALL [6].
2.2. IL-7R signaling cascade and Ig rearrangement
There has been discussion regarding the relationship between IL-7R signal cascades RAG1/2
(recombination activating gene 1/2) that mediate Ig rearrangement. In fact, it is not clear how
transcription factors mediate transcriptional repression of Rag. Recombination activating implies
that this gene is involved in immunoglobulin V-D-J recombination. The cleavage activity of
RAG1 requires RAG2 as a partner. The RAG-1/2 complex nicks the Recombination Signal Sequ-
ence (RSS) that flanks the V, D, and J regions.
In the RAG1/RAG2 complex, RAG1 has the most catalytic activity while RAG2 provides a
binding scaffold for the tight association with DNA [11]. There has been a controversial discus-
sion in previous reports that the IL-7R pathway may enhance or suppress recombination. To
explain the opposing effect of IL-7, it acts on Ig rearrangement in a dose-dependent manner. RSSs
consists of three elements, heptamer sequences, spacer sequences, and nonamer sequences that
flanks the V, D, and J sequences in the IgH and the V and J sequences in the IgL region. Spacer
sequences are either 12 base pairs or 23 base pairs long and are located between the heptamer
and nonamer sequences. Heptamer sequences are CACAGTG and nonamers are usually
ACAAAAACC. After rearrangement, RSSs are spliced out of the final Ig mRNA. When B cells
undergo IgH rearrangement, IL-7R expression increases, suggesting that IL-7R may be associ-
ated with the rearrangement. However, the downstream molecule Stat5 may contribute to
suppression of the rearrangement. As a candidate for the suppression effect, Ebf1 expression is
promoted by Stat5, suggesting a link between the negative regulations of Rag transcription [12].
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Using model mice with Stat5 high expression, the IgH rearrangement was repressed. A sche-
matic representation of immunoglobulin loci is illustrated below (Figures 1 and 2).
2.3. PreBCR and surrogate light chain
PreBCR is expressed on a large pre-B cell after or during IgH rearrangement. This contains a
surrogate light chain consisting of VpreB and lambda 5. In addition, CD79a, CD79b, and the Ig
muH chain participate in the formation of preBCR. Although it is not clear how antigens or
ligands stimulate preBCR, signaling through preBCR controls allelic exclusion. One of the IgH
locus rearrangements is inactive, promotes proliferation, and induces differentiation to small
pre-B cells. IgL rearrangement follows this expression of preBCR. IgL rearrangement proceeds
after the expression of preBCR in small pre-B cells. CD79a and CD79b contain tyrosine-rich
ITAMs that can recruit the cytosolic SRC homology 2 (SH2)-domain-containing SYK following
phosphorylation of the immunoreceptor tyrosine-based activation motifs (ITAMs). One of the
pan-B cell markers, CD19 and CD45, interact with the preBCR to serve as regulators of positive
signaling. In contrast, negative signaling and the regulatory mechanisms of preBCR have not
been sufficiently addressed, Therefore, preBCR signaling has not been elucidated. It is possible
that immunoreceptor tyrosine-based inhibitory motifs (ITIMs) function to recruit cytosolic
Figure 1. A scheme of B cell differentiation and immunoglobulin rearrangement.
Figure 2. Immunoglobulin gene loci. VH, variable segment; D, diverse segment, J, junction segment. Vk, variable
segment of kappa light chain.
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protein tyrosine phosphatases (PTPs) such as SH2-domain-containing PTP 1 (SHP1). PIK3K is
another adaptor protein of the CD79a and CD79b heterodimer. The RAS-ERK cascade and
AKT-FOXO cascade may induce a positive signal inducing proliferation and BCl6, a marker of
diffuse large B cell lymphoma/leukemia that may induce B cell lineage proliferation.
SYK can associate with other protein kinases, LYN and Slp65 /BLK or BLNK, that recruit BTK in a
phosphorylation dependent manner. BTK associates with SLP-65, also known as BLNK or BASH,
another important linker protein. BLNK suppresses Pre-B cell leukemogenesis through JAK3
inhibition [13–15]. BLNK KOmice developed pre-B cells or ALL in an experimental study. BLNK
is part of a signaling complex involving Grb-2 and Vav, prior to arrangement of the cytoskeleton.
BLNK, BTK, and PLCgamma 2 may form a complex that promotes IRF4 expression linked to IgL
rearrangement that suppresses or downregulates the preBCR and IL-7R signal cascades simulta-
neously. In this way, the transition of IgH rearrangement to IgL rearrangement is controlled by the
orchestration of various kinases and adaptor proteins. BLNK is involved in switching cell fate
from proliferation to differentiation [16]. Additionally, BLNK recruits active H-Ras to the BCR
complex, which is essential for sustained BCR surface expression and for the signal leading to
functional ERK activation [17], potentially resulting in B-cell proliferation. Upregulation of BLNK
may be a consequence of the negative-feedback mechanism and this upregulation results in
tumor suppression. BLNK knockdown resulted in downregulation of BP-1, a pre-B cell marker
[18]. Mice deficient in Slp65 /Blnk spontaneously develop pre-B cell leukemia [13], originating
from pro-B cells with V(H)-to D-J(H) recombination. Nevertheless, IgH rearrangement was
restricted to V(H)14-1 and V(H)14-2, V(H)14 IgH chains did not provide increased proliferative
signals. PreBCR specificity did not contribute to oncogenic transformation.
Ikaros is required for the differentiation of large pre-B to small pre-B cells and is also required
for the down-regulation of the preBCR, Igκ germline transcription, and IgL chain recombina-
tion. The Ikaros family are regulators of B-cell development by DNA-binding. Ikaros functions
as a tumor suppressor in pre-B ALL [19] by controlling BCR-ABL1 kinase signaling from SRC
kinase-activation to BLNK [20] or c-Myc expression [21]. Interestingly, BCR-ABL1 induces
aberrant splicing of Ikaros in pre-B ALL [22]. The loss of Ikaros DNA-binding function leads
to the progression of acute lymphoblastic leukemia [23]. Recently, MLL1 is found to be a
regulator of preBCR signaling [24].
2.4. Orchestration of the preBCR and IL-7R signal cascades
In developing B cells, the IL-7R and preBCR synergize or act exclusively to induce proliferation
[25]. However, preBCR is also critical to control differentiation through suppression of c-Myc
function in large preB cells [26]. PreBCR is thus timely expressed in the transition of large to
small preB cells [27]. PreBCR signaling does not affect interactions between the intronic enhancer
and V (kappa) genes in proB cells. The kappa enhancers interact with the V (kappa) region
already in proB cells. PreBCR signaling induces accessibility through functional redistribution of
long-range chromatin interactions within the V(kappa) region [28]. ZFP521 expression during
cell growth is attenuated by the addition of IL-7 [16, 29]. Stimulation of preBCR modulated the
growth of ZFP521-overexpressing cells [25]. IL-7 and preBCR control the development of preB
cells into mature B cells [27, 30]. When IL-7R expression is gradually attenuated during the late
stage of large preB cell development, preBCR signaling replaces the dominant pathway. B-cell
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development is controlled in a stepwise manner where the first stage of development is com-
pleted before the subsequent stages are initiated.
There has been discussion as to whether preBCR functions as a tumor suppressor in the all
cases of human acute lymphoblastic leukemia lymphoma (ALL). A distinct subset of human
ALL is sensitive to preBCR [31]. The effects of preBCR stimulation were attenuated by the
addition of IL-7 [16, 29]. Although both pathways are orchestrated during B-cell development
[27], they are linked with immunoglobulin rearrangement [32]. During the development of
pro-B cells into pre-B cells, IL-7 signaling is a major mediator with IL-7R expressed at high
levels. In contrast, during the development of pre-B cells into mature B cells, preBCR signaling
may be the dominant pathway after IL-7R expression is attenuated. Thereafter, mature BCR
replaces preBCR. B-cell development is controlled in a stepwise manner in which the first stage
of development is completed before the subsequent stages are initiated. In summary, the
relationship between preBCR and the IL-7R cascade is complicated and forms an interactive
network. The outcome of pre-B cell stimulation is difficult to predict in terms of proliferation or
development. This network may be a necessary checkpoint for the developmental stage in a
dose-dependent of IL-7 and other stimuli (Figure 3).
2.5. Other candidate cascades in pre-B cells
We previously reported that MLV insertion into the signal transducer and activator of transcrip-
tion factor 5 (Stat5), Homeodomain-interacting protein kinase 2 (Hipk2), and Flt3-interacting
zinc finger protein 1 (Fiz1) in the pre-B cell lymphoma genome. These genes encode proteins
Figure 3. The interactive responsiveness to stimulation through preBCR, IL-7, and other signaling cascades. In this
scheme, bank 1 is selected for the modulator that is controlled by zfp521.
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that are involved in pre-B cell-specific molecular signaling pathways such as IL-7R, CD43, and
Fms-like tyrosine kinase 3 (FLT3). The dysregulation of this preBCR signal is responsible for
pre-B cell lymphomagenesis [33]. ZFP521 contributed to mouse and human pre-B-cell
lymphomagenesis (i.e., human B-cell lymphoblastic lymphoma). Pre-B cell proliferation
depended on the activation of preBCR signaling molecules, which were upregulated by
ZFP521.
2.6. Pre-B cell and acute lymphoblastic neoplasia in mouse
To date, pre-B cell lines from acute lymphoid tumors require strict cell culture conditions and
consistent time course research. Using these cell line, IL-7 supply is critical, but IL-7 and v-Ha-
ras expression are not individually sufficient to induce tumorigenicity. Their co-expression
yields highly tumorigenic pre-B lymphoid cell lines [34].
On the other hand, as an experimental model, SL/Kh is known to be useful for tumorigenesis
of pre-B cells and signaling pathways. This strain has two copies of AKV endogenous MLV
and other retrovirus-derived fragments [3]. The expressed viral vector infects the host B cell
progenitors and retroviral elements, such as promoters and enhancers promote Stat5, c-myc,
ZFP521, N-myc, and other oncogenes [3, 6, 18, 35–37]. For this, this strain serves as an appro-
priate model for analysis of interaction between these molecules and their related signal
pathways.
2.7. Role of ZFP521 during lymphoid differentiation
The mechanisms by which preBCR-related genes are controlled are not sufficiently understood
relative to the mature B cell receptor. ZFP521 has been recently recognized as an important
gene in pre-B cell lymphomagenesis. When ZFP521 is upregulated, BTK, BLNK, and BANK1
are involved in the preBCR signaling pathway and are comprehensively upregulated. ZFP521
contributes to the upregulation of Ccnd3 and Ccnd2, enhancing the cell cycle and inducing
proliferation. In a previous study, preBCR also activates the Ras-MEK-extracellular signal-
regulated kinase (ERK) pathway, cell cycle exit, and light chain recombination by silencing
Ccnd3 [38]. Ccnd3 gene expression is probably responsible for the growth of pre-B cells [39].
BTK1 and BANK1 are downstream of preBCR or BCR is controlled by ZFP521 and upregul-
ation of BTK1 and BANK1 contributes to pre-B cell proliferation.
BANK1 is a modulator of the pre-B cell signaling pathway disrupted by IL-7R signaling that
interacts with phospholipase gamma2 [40]. Overexpression of BANK1 enhances BCR-induced
calcium mobilization. Another lymphocytic associated kinase, LYN, associates with BANK1.
LYN is activated with catalyst tyrosine phosphorylation of IP3R (Inositol 1,4,5-trisphosphate
receptor).
BTK is a useful diagnostic marker for Hodgkin’s and B-cell non-Hodgkin’s lymphoma [41].
BTK-dependent pathways are involved in maintaining the malignant phenotype in B-cell
lymphomas and leukemias [31, 42–44]. Anti-apoptosis signaling in various B-cell malignancies
requires BTK-dependent signals from the B-cell antigen receptor. A distinct subset of human
ALL is selectively sensitive to preBCR antagonists, such as those employed for ibrutinib
therapy for B cell malignancy [31, 42–44] In contrast, several reports suggested that BTK acts
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as a tumor suppressor in the majority of human ALL cases [31, 41]. The BTK-dependent
pathway is controlled in an expression dependent manner. Additionally, overexpressed BTK
affects the survival or selection of B cells during the development of malignancies [45] and
contributes to malignant transformation.
In humans, fusion of the Pax5 exon 7 to ZNF521 exon 4 has been observed in pre-B cell acute
lymphocytic leukemia by genome-wide analysis of genetic alterations [46]. Importantly, this
breakpoint is located near the conserved integration target sequence in human ZNF521,
suggesting that the locus is active in pre-B cells as in Pax5, which is essential for pre-B cell
development. Thus, we can conclude that aberrant release of the ZFP521 gene control leads to
pre-B cell lymphomagenesis through activation of pre-B cell-specific molecular signaling path-
ways. Moreover, c-Jun expression was observed in lymphoma tissues exhibiting ZFP521
overexpression, suggesting that c-Jun is associated with lymphomagenesis [25].
MLV insertion into ZFP521 gene was observed in the lymphomas with its insertion to Sat5,
Hipk2, or Fiz1 genes. These target tgenes may interact in the development of pre-B lymphoma.
The dysregulation of this preBCR signal is responsible for pre-B cell lymphomagenesis [33].
ZFP521 contributes to mouse and human pre-B cell lymphomagenesis (i.e., human B-cell
lymphoblastic lymphoma). Pre-B cell proliferation depends on activation of preBCR signaling
molecules including BANK1, which are upregulated by ZFP521.
ZFP521 is involved in tumorigenesis in pre-B cell lymphoblastic lymphoma through upregulation
of preBCR signaling molecules, interfering with the IL-7R signaling pathway. ZFP521 also medi-
ates the expression of Ccnd3, c-jun, and other cell cycle-related genes. Therefore, these data
suggested that ZFP521 might be a promising target for targeted molecular therapy for ALL or
B-precursor lymphoma.
3. Conclusion
The early stage of B cell differentiation is characterized by immunoglobulin rearrangement.
Rearrangement is controlled by both the enzyme RAG 1/2, and IL-7R and preBCR signaling
pathways. These two pathways sometimes function cooperatively, sometimes antagonistically
and seem to support the timing of immunoglobulin gene rearrangement.
4. Materials
4.1. SL/Kh strain
SL/Kh is an inbred mouse strain that shares the AKV1 pro-virus with the AKR strain, which is
susceptible to T cell leukemia/lymphoma [3]. This strain has been developed over 30 years
through brother-sister mating and acquired susceptibility to MLV-mediated pre-B lymphoma
[47]. AKV was mapped as the endogenous ecotropic murine virus 11 (Emv11) onto chromosome
7 [48, 49]. In this strain, the pro- to pre-B cells expand in the bone marrow in a polyclonal
manner before monoclonal expansion [18]. Afterwards, more than one copy of the proviral
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genome is acquired during the development of lymphomagenesis. More than 90% of these
mice spontaneously develop sIgM pro- or pre-B lymphomas, positive for preBCR, by 6 months
of age. MLV genomes were integrated into Stat5, c-Myc, ZFP521, and other oncogenes in the
lymphoma cell genome. Upregulation in expression of Stat5 and ZFP521 are not sufficient, as
pre-B cell lymphomagenesis and a strain-dependent background are required [50, 51].
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ZFP521 zinc finger protein 521
Stat5a signal transducer and activator of transcription
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